Skip to content

Observation of the efficacy of Gu-Ben-Hua-Shi-Qu-Feng Formula in the treatment of patients with atopic dermatitis (spleen deficiency with dampness pattern)

Observation of the efficacy of Gu-Ben-Hua-Shi-Qu-Feng Formula in the treatment of patients with atopic dermatitis (Spleen deficiency with dampness pattern)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000034
Enrollment
Unknown
Registered
2026-01-08
Start date
2025-05-06
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

Treatment Groups:Gu-Ben-Hua-Shi-Qu-Feng Formula

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meeting both the Hanifin-Rajka diagnostic criteria for atopic dermatitis and the TCM pattern differentiation points for spleen deficiency with dampness pattern as outlined in the International Clinical Practice Guideline for Traditional Chinese Medicine: Atopic Dermatitis;(2) Aged 6 to 65 years ;regardless of sex;(3) SCORAD score between 25 and 50 points;(4) Voluntarily agree to participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating patients; patients (male or female) with reproductive planning;(2) Individuals with known hypersensitivity to the investigational drug or its components;(3) Patients with underlying diseases that may interfere with treatment or study outcomes including but not limited to: diabetes mellitus cardiovascular/cerebrovascular disorders severe primary hepatic/renal diseases favism coagulopathies psychiatric disorders malignancies; concurrent infectious diseases (e.g. tuberculosis hepatitis); or immunodeficiency syndromes;(4) Patients with concomitant skin diseases affecting lesion assessment (e.g. scabies psoriasis seborrheic dermatitis);(5) Patients demonstrating poor compliance inability to cooperate with clinical observation or current participation in other drug trials.

Design outcomes

Primary

MeasureTime frame
Pruritus VAS;SCORAD;

Secondary

MeasureTime frame
EASI;IL-4;IL-13;IGA;POEM;IL-5;IgE;Eosinophil;DLQI/CDLQI;Sleep VAS;SCH;TWEL;

Countries

China

Contacts

Public ContactMoXiumei

No.111 Dade Road Yuexiu District Guangzhou City Guangdong Province China

moxiumeilsamay@163.com13650755038

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026